Methods for identification of coronaviruses

• US 8,057,993 B2
• Filed: 04/22/2004
• Issued: 11/15/2011
• Est. Priority Date: 04/26/2003
• Status: Expired due to Fees

• Current Assignee: Ibis Biosciences Incorporated (Abbott Laboratories)
• Original Assignee: Ibis Biosciences Incorporated (Abbott Laboratories)
• Inventors: Hofstadler, Steven A., Sampath, Rangarajan, Hall, Thomas A., Massire, Christian, Blyn, Lawrence B., Ecker, David J.
• Primary Examiner(s): BAUSCH, SARAE L
• Application Number:
  US10/829,826
• Publication Number:
  US 20050266397A1
• Time in Patent Office: 2,763 Days
• Field of Search: None
• US Class Current: 435/6
• CPC Class Codes: C12N 2770/20011 Coronaviridae
• CPC Class Codes: C12Q 1/701 Specific hybridization probes
• CPC Class Codes: Y10T 436/24 Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry

Abstract

The present invention provides a method for rapid identification and quantitation of bacteria by amplification of a segment of bacterial nucleic acid followed by analysis by mass spectrometry. The compositions provide for characterization of the molecular masses and base compositions of bacterial nucleic acids which are used to rapidly identify bacteria.

Claims

1. A multiplex polymerase chain reaction method for identifying a coronavirus, comprising:

a) providing a sample suspected of comprising one or more coronavirus family members, wherein the identity of said coronavirus family members is unknown;

b) providing coronavirus RNA from said sample, wherein the identity of the coronavirus source of said coronavirus RNA is unknown;

c) providing corresponding DNA from said RNA wherein said DNA comprises sequences encoding at least a portion of a nsp11 gene and at least a portion of a RdRp gene;

d) amplifying said DNA to produce first and second amplification products using two or more oligonucleotide primer pairs, wherein said first amplification product comprises sequences encoding at least a portion of said nsp11 gene and said second amplification product comprises sequences encoding at least a portion of said RdRp gene;

e) determining the base compositions of said first and second amplification products by mass spectrometry without sequencing said first and second amplification products, wherein said base compositions identifies the number of A residues, C residues, T residues, G residues, U residues, analogs thereof and mass tag residues thereof in said first and second amplification products;

f) comparing said base compositions of said first and second amplification products to calculated or measured base compositions of corresponding amplification products of one or more known coronaviruses present in a database with the proviso that sequencing of said first and second amplification products is not used to identify said coronavirus, wherein a match between said determined base compositions and said calculated or measured base composition in said database identifies the identity of said one or more coronavirus family members in said sample; and

g) determining the identity of said one or more coronavirus family members by identifying a match between said determined based compositions and said calculated or measured base composition in said database.

2. The method of claim 1, wherein said two or more oligonucleotide primer pairs comprise primer pair SEQ ID NO:

5 and SEQ ID NO;

6, and at least one additional primer pair selected from the group consisting of SEQ ID NO;

7 and SEQ ID NO;

8, SEQ ID NO;

9 and SEQ ID NO;

8, SEQ ID NO;

9 and SEQ ID NO;

10, SEQ ID NO;

11 and SEQ ID NO;

8, and SEQ ID NO;

11 and SEQ ID NO;

10.

3. The method of claim 1, wherein said amplifying is carried out in a single reaction well.

4. The method of claim 1, wherein said amplifying is carried out in primer pair specific reaction wells.

5. The method of claim 1, wherein one or more coronavirus family members are identified in the sample, the identified family members comprising one or more of Canine coronavirus, Feline coronavirus, Human coronavirus 229E, Human coronavirus OC43, Porcine epidemic diarrhea virus, Transmissible gastroenteritis virus, Bovine coronavirus, Murine hepatitis virus, Porcine hemagglutinating encephalomyelitis virus, Rat coronavirus, Turkey coronavirus, Avian infectious bronchitis virus, and SARS coronavirus.

6. The method of claim 1, wherein said mass spectrometry comprises ESI-TOF mass spectrometry.

7. A multiplex polymerase chain reaction method for identifying a coronavirus, comprising:

a) providing a sample suspected of comprising one or more coronavirus family members, wherein the identity of said coronavirus family members is unknown;

b) providing coronavirus RNA from said sample, wherein the identity of the coronavirus source of said coronavirus RNA is unknown;

c) providing corresponding DNA from said RNA wherein said DNA comprises sequences encoding at least a portion of a nsp11 gene and at least a portion of a RdRp gene;

d) amplifying said DNA with a first primer pair to produce a first amplification product that comprises sequences encoding at least a portion of said nsp11 gene, wherein said first primer pair comprises;

i) a forward primer with at least 70% sequence identity with SEQ ID NO;

5, and ii) a reverse primer with at least 70% identity with SEQ ID NO;

6;

e) amplifying said DNA with a second primer pair to produce a second amplification product that comprises sequences encoding at least a portion of said RdRp gene;

f) determining the base compositions of said first and second amplification products by mass spectrometry without sequencing said first and second amplification products, wherein said base compositions identifies the number of A residues, C residues, T residues, G residues, U residues, analogs thereof and mass tag residues thereof in said first and second amplification products;

g) comparing said base compositions of said first and second amplification products to calculated or measured base compositions of corresponding amplification products of one or more known coronaviruses present in a database with the proviso that sequencing of said first and second amplification products is not used to identify said coronavirus, wherein a match between said determined base compositions and said calculated or measured base composition in said database identifies the identity of said one or more coronavirus family members in said sample; and

h) determining the identity of said one or more coronavirus family members by identifying a match between said determined based compositions and said calculated or measured base composition in said database.